AQST Aquestive Therapeutics

Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference

WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference to be held December 1-3, 2020. Aquestive will host one-on-one investor meetings on December 2, 2020.

A webcast of the fireside chat will be available on the "Events and Presentation" page of the Investors section of the Company's website. A replay of webcast will be available for 30 days following the event. For more information, please visit .

About Aquestive Therapeutics

Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. The Company has commercialized one internally-developed proprietary product to date, Sympazan, has a commercial proprietary product pipeline focused on the treatment of diseases of the central nervous system, or CNS, and other unmet needs, and is developing orally administered complex molecules to provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.

Investor inquiries:

Stephanie Carrington



646-277-1282

 



EN
25/11/2020

Underlying

AQSTAquestive Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aquestive Therapeutics

 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibu...

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting Anaphylm™ (dibutepinephrine) sublingual film achieved clinically relevant epinephrine plasma concentrations without diastolic blood pressure dip WARREN, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that multiple poster prese...

23h / 45m 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Appoints Internationally Recognized Allergist D...

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appo...

February 18, 2026 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Announces FDA Issuance of Complete Response Let...

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™ Deficiencies limited to packaging and administrationCompany believes it can rapidly resolve deficiencies and expects to resubmit as early as Q3 2026Remains well-capitalized and anticipates ending 2026 with significant cashReiterates plans to submit in Canada and EU by the end of 2026Company to host investor call on February 2, 2026, at 8:00am ET WARREN, N.J., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing...

February 2, 2026 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ ...

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update Announces receipt of FDA letter stating it has identified deficiencies that preclude labeling discussions for Anaphylm at this time Receives confirmation from FDA that Agency’s review of Anaphylm NDA application is ongoing and no final FDA decision has been madeProgresses global regulatory expansion activities in Canada, Europe, and the United Kingdom for AnaphylmUnaudited cash and cash equivalents of approximately $120 million as of December 31, 2025 WARREN...

January 9, 2026 1 EN
 PRESS RELEASE
Free
AQST Aquestive Thera...

Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual...

Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference WARREN, N.J., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the upcoming Piper Sandler 37th Annual Healthcare Conference December 2-4, 2025, in New York City. The Aquestive team will hold a fireside chat with Piper Sa...

November 24, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch